Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
I know it’s not going to happen but I would love to see AS up there one day explaining the benefits of LFTs (and why AffiDX is so much better than the LFTs that have been used before). He communicates so clearly it would be awesome to hear him talking to the public. I genuinely believe as well as being great for Avacta he could make a real difference to the amount of understanding (and testing) in the country
Just done a bit of research into these guys and this looks like good news to me.
Their tech reads LFTs even when the lines are hard to read. Based on what we know that would turn AffiDX into a 10 minute LFT. It also captures location data for where positive and negative tests have been taken which will be enormously useful for the government. It’s available as a standalone app or as an SDK which means it can be integrated into other apps.
They’ve been granted emergency use to be used with Innova but the RNS makes it clear that is only because right now Innova is the only authorised test and they will be working with other tests when authorised.
I like the sound of this a lot as it adds even more utility to LFTs which can only be good for the best LFT out there
Sorry, not sure what we should be taking from the link?
Definitely crossed my mind that something has happened with Fincap, they’ve had a massive spread for days and not been anywhere need the bid or ask and this has gone even further to a 100 point spread today.
May have been a falling out. Is there something I should take from the LSE link though?
Some of the bigger orders pushed up their price through the auction too.
One order for just over 27k shares started at 250 and was at 256 by the time it closed. Some other big orders increased their bid price during the auction too. Looks like they didn’t all get filled by any means
Yes, I thought this too when I saw it last week.
Previous comments indicated they were getting samples / testing it against them in the UK then announced last week that it worked.
Could only have come from uk validation I believe
Massive is an understatement!!!
- Confirmed detects SA variant
- In active discussions with Dept of Health as commercial route to UK market
- Aware of very significant demand in Europe
- US demand too, worried about being able to manufacture enough
- 30m UK manufacturing a month
- Overseas manufacturing on top of that
- Extra detail on the CV was awesome
This is the best investment opportunity I think I have ever seen!!!
I totally agree.
Licensing is where the projections start to turn just a little a bit crazy.
If mass screening takes off across the developed world you’re talking perhaps a billion LFTs a week.
Now if affimers powered even 10% of that though licensing deals that’s 100m units a week. Who knows what the margin would be but even at a conservative 50p that would be £2.5bn profit per year. And that’s only on 10% and 50p. You could potentially double those margins and exponentially increase the 10%.
Selling our own product in high volumes will be incredibly, incredibly profitable, licensing the tech to other manufacturers in exponential volumes could be off the scale profitable
So to reiterate what we’ve learned this morning:
- Multiple manufacturing partners already lined up including undisclosed ones (reference to ‘and others’
- Up to 30m units a month from UK manufacturing alone with overseas manufacturing coming on top
- Active negotiations with distributors in 25 countries
- Governments (plural), healthcare providers and corporates testing workforces initial target customers
- Talking to licensing partners confirmed(this to me is the most exciting, licence the product to OEMs around the world and sales could quickly get into hundreds of millions a month)
- Large scale end user demand is strong
This just gets more and more exciting. Looking forward to the webinar!!!!!!
Fincap: With this major derailing event behind us and confirmation that GAD has manufactured batches at scale we now look forward to commercial deals, given that Avacta is in ACTIVE DISCUSSION with distributors in 25 EU markets’
Great quotes:
‘The collaboration with Mologic also provides initial manufacturing capacity with the benefit of a short set-up time for the lateral flow test with Global Access Diagnostics ('GAD'), in addition to the agreements with BBI Group, Abingdon Health and others, that will provide manufacturing capabilities’
Note the AND OTHERS
‘We are now very close to self-declaration of the CE mark of the AffiDX® rapid antigen test for professional use and commercial launch in early May. We have made very good commercial progress with potential distributors, licensing partners and large-scale end users and demand is strong’
Distributors and LICENSING PARTNERS
Exciting times!
Interesting announcement from Boris tonight about fast tracking potential treatments - including treatments you can take at home if you test positive or if someone in your household tests positive.
Foralumab anyone?
This really could go on to sell literally billions of units and be licensed to manufacturers all over the world.
Identifying 100% of users with an infectious load equal to a CT cycle of under 27 in under 10 minutes is utterly priceless.
This really could mean hundreds of thousands of lives saved and economies opened up all over the world